Paris
Capstone’s Paris office provides investor and corporate clients with on the ground insights on European regulatory issues and beyond.
15 Rue Feydeau, Room 309
75002 Paris, France
Our Latest Insights
FDA Cracks Down on GLP-1 Compounding While Bolstering Peptides and Hormone Therapies
Capstone believes that while continued scrutiny by the Food and Drug Administration (FDA) has ended large-scale GLP-1 compounding, non-GLP-1 product categories are unlikely to face targeted enforcement. Products such as peptides and hormone therapies are also likely...
Germany’s Far-Right Gains Pose Regional Renewables Risk, but No National Threat
The Alternative for Germany (AfD), a far-right party, achieved historic gains in two state elections in September and is seeking to form Germany’s first far-right-led state government since World War II. This has raised concerns over the outlook for the renewables...
What Investors Should Know About Washington’s First Corporate Practice of Medicine Bill
Capstone believes the Stop Corporate Takeovers of Physicians Act, the first corporate practice of medicine (CPOM) legislation at the federal level, marks a departure from CPOM’s history as a state-regulated matter. The bill is based on Oregon’s SB 951, a model...


























